AT340590T - Against human interleukin-8 directed, reconstituted human antibody - Google Patents

Against human interleukin-8 directed, reconstituted human antibody

Info

Publication number
AT340590T
AT340590T AT95925116T AT95925116T AT340590T AT 340590 T AT340590 T AT 340590T AT 95925116 T AT95925116 T AT 95925116T AT 95925116 T AT95925116 T AT 95925116T AT 340590 T AT340590 T AT 340590T
Authority
AT
Austria
Prior art keywords
directed
reconstituted
interleukin
human antibody
against
Prior art date
Application number
AT95925116T
Other languages
German (de)
Inventor
Kouji Matsushima
Yoshihiro Matsumoto
Yoshiki Yamada
Koh Sato
Masayuki Tsuchiya
Tatsumi Yamazaki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP16148194 priority Critical
Priority to JP28995194 priority
Priority to JP31078594 priority
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AT340590T publication Critical patent/AT340590T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
AT95925116T 1994-07-13 1995-07-12 Against human interleukin-8 directed, reconstituted human antibody AT340590T (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP16148194 1994-07-13
JP28995194 1994-11-24
JP31078594 1994-12-14

Publications (1)

Publication Number Publication Date
AT340590T true AT340590T (en) 2006-10-15

Family

ID=27321865

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95925116T AT340590T (en) 1994-07-13 1995-07-12 Against human interleukin-8 directed, reconstituted human antibody

Country Status (10)

Country Link
US (3) US5994524A (en)
EP (1) EP0770628B9 (en)
KR (1) KR100261941B1 (en)
AT (1) AT340590T (en)
AU (1) AU701342B2 (en)
CA (1) CA2194907A1 (en)
DE (2) DE69535243D1 (en)
HU (1) HU221385B1 (en)
WO (1) WO1996002576A1 (en)
ZA (1) ZA9505832B (en)

Families Citing this family (264)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2181787A1 (en) * 1994-03-03 1995-09-08 Claire M. Doerschuk Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
AU2576697A (en) * 1996-04-19 1997-11-12 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient
EP0966971A4 (en) 1996-04-23 1999-12-29
AU2405197A (en) * 1996-04-23 1997-11-12 Chugai Seiyaku Kabushiki Kaisha Myocardial infarction remedy containing anti-il-8 antibody as active ingredient
KR20000022238A (en) * 1996-06-26 2000-04-25 나가야마 오사무 Remedies for acute pulmonary injuries due to indirect causes containing anti-il-8 antibody as the active ingredient
WO1998017312A1 (en) * 1996-10-22 1998-04-30 Chugai Seiyaku Kabushiki Kaisha Sepsis remedy comprising anti-il-8 antibody as active ingredient
US6025158A (en) * 1997-02-21 2000-02-15 Genentech, Inc. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
AU746819B2 (en) 1997-02-21 2002-05-02 Genentech Inc. Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
WO1999037779A1 (en) * 1998-01-22 1999-07-29 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
AT547119T (en) 1997-03-21 2012-03-15 Chugai Pharmaceutical Co Ltd Preventive or therapeutic agent with an il-6 antagonist as an active substance for sensitized t cells
CN1326565C (en) 1997-10-14 2007-07-18 中外制药株式会社 Potentiator for antibody against lymphoid tumor
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
CA2341029A1 (en) * 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CA2341638C (en) * 1998-08-24 2010-05-11 Meiji Milk Products Co., Ltd. Use of a midkine inhibitor
JP4671570B2 (en) 1999-08-23 2011-04-20 中外製薬株式会社 HM1.24 antigen expression enhancer
AU7450600A (en) 1999-10-01 2001-05-10 Chugai Seiyaku Kabushiki Kaisha Prevention and treatment of diseases associated with blood coagulation
EP1987842A1 (en) 2000-04-28 2008-11-05 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitor
EP1849479A1 (en) 2000-08-16 2007-10-31 Chugai Seiyaku Kabushiki Kaisha Ameliorating agent for symptoms resulting from joint diseases
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20060063152A1 (en) 2000-12-22 2006-03-23 Osamu Ohara Novel gene and protein encoded by the gene
JP3986439B2 (en) 2001-02-07 2007-10-03 中外製薬株式会社 Hematopoietic tumor therapeutic agent
CN1789416B (en) 2001-05-11 2011-11-16 协和发酵麒麟株式会社 Human artificial chromosome containing human antibody lambda light chain
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
CA2474943C (en) 2002-02-14 2016-06-07 Chugai Seiyaku Kabushiki Kaisha Sugar stabilized antibody-containing solution formulations
WO2003078595A2 (en) * 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
JP4753578B2 (en) * 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド Synthetic antibody phage library
AU2003257536A1 (en) 2002-08-27 2004-03-19 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein solution preparation
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
US8420789B2 (en) 2002-09-11 2013-04-16 Chugai Seiyaku Kabushiki Kaisha Method for removing DNA contaminants from a protein-containing sample
WO2004058797A2 (en) 2002-12-16 2004-07-15 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (il-8)
JP2006522806A (en) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス,インコーポレイテッド Selected RNA motifs for inducing cell death and / or apoptosis
DE602004028249D1 (en) 2003-06-18 2010-09-02 Chugai Pharmaceutical Co Ltd Fucosetransporter
US20070025992A1 (en) * 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
JP4643450B2 (en) 2003-08-08 2011-03-02 中外製薬株式会社 Cancer high expression gene
WO2005074417A2 (en) * 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
WO2005035753A1 (en) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP2311945A1 (en) 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies substituting for functional proteins
FI122368B (en) * 2003-11-06 2011-12-30 Valtion Teknillinen A process for making a porous plastic film and a plastic film
JP4637749B2 (en) 2003-11-11 2011-02-23 中外製薬株式会社 Humanized anti-CD47 antibody
WO2006006693A1 (en) 2004-07-09 2006-01-19 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
EP1831258B1 (en) * 2004-12-28 2015-10-14 Innate Pharma S.A. Monoclonal antibodies against nkg2a
TWI671403B (en) 2005-03-31 2019-09-11 中外製藥股份有限公司 Method for controlling controlled assembly of polypeptide
PT1876236E (en) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Antibody substituting for function of blood coagulation factor viii
KR101367544B1 (en) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 Stabilizer for protein preparation comprising meglumine and use thereof
TW200718780A (en) 2005-06-10 2007-05-16 Chugai Pharmaceutical Co Ltd Sc(Fv)2 site-directed mutant
KR101323563B1 (en) 2005-10-18 2013-10-29 니토 보세키 가부시기가이샤 Antibody-producing transgenic silkworms and methods for producing the same
WO2007056113A2 (en) * 2005-11-02 2007-05-18 Cylene Pharmaceuticals, Inc. Methods for targeting quadruplex sequences
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
WO2007114325A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
KR101463631B1 (en) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 Method for control of blood kinetics of antibody
US20090220524A1 (en) 2006-04-25 2009-09-03 The University Of Tokyo Therapeutic agents for alzheimer's disease and cancer
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
KR20150091545A (en) 2006-06-08 2015-08-11 추가이 세이야쿠 가부시키가이샤 Preventive or remedy for inflammatory disease
JPWO2007145227A1 (en) 2006-06-14 2009-11-05 中外製薬株式会社 Hematopoietic stem cell increase promoter
JP5028635B2 (en) 2006-06-21 2012-09-19 オンコセラピー・サイエンス株式会社 Tumor-targeted monoclonal antibodies against FZD10 and uses thereof
RU2499001C2 (en) 2006-06-30 2013-11-20 Ново Нордиск А/С Antibodies to nkg2a and their applications
PE20081004A1 (en) 2006-07-13 2008-09-18 Chugai Pharmaceutical Co Ltd Cell death-inducing agents
US8025881B2 (en) 2006-07-21 2011-09-27 Chugai Seiyaku Kabushiki Kaisha BMP antibodies and methods of treating kidney disease using the same
EP1882697B1 (en) 2006-07-24 2010-04-21 Institut Pasteur Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins
AU2007285217B2 (en) 2006-08-14 2013-02-07 Forerunner Pharma Research Co., Ltd Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
US9017684B2 (en) 2006-10-12 2015-04-28 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
WO2008047914A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Cancer therapeutic agent comprising anti-hb-egf antibody as active ingredient
WO2008047925A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US20100111852A1 (en) 2006-12-14 2010-05-06 Forerunner Pharma Research Co., Ltd. Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
EP2123676A4 (en) 2007-01-05 2011-01-05 Univ Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
JP5299902B2 (en) 2007-01-30 2013-09-25 中外製薬株式会社 Chimeric Fcγ receptor and ADCC activity measurement method using the receptor
CN101951953A (en) 2007-02-27 2011-01-19 株式会社未来创药研究所 Contain the pharmaceutical composition of anti-GRP78 antibody as effective ingredient
CL2008000719A1 (en) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Therapeutic agent for cancer resistant to chemotherapeutic agents comprising an antibody that recognizes HLA class I as an active ingredient; pharmaceutical composition comprising said antibody; and method of treating cancer resistant
JP5117765B2 (en) * 2007-05-28 2013-01-16 国立大学法人 東京大学 Tumor diagnostic agent for PET containing anti-ROBO1 antibody
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
WO2009001840A1 (en) 2007-06-25 2008-12-31 Forerunner Pharma Research Co., Ltd. Anti-prominin-1 antibody having adcc activity or cdc activity
US8536313B2 (en) 2007-07-10 2013-09-17 Shionogi & Co., Ltd. Monoclonal antibody having neutralizing activity against MMP13
AU2008304778B9 (en) 2007-09-26 2014-05-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
NZ584769A (en) 2007-09-28 2011-09-30 Chugai Pharmaceutical Co Ltd Anti-glypican-3 antibody having improved kinetics in plasma
CL2009000647A1 (en) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent to attenuate a side effect comprising said antibody; method for treating or preventing liver cancer in a subject.
WO2009051108A1 (en) 2007-10-15 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Method for production of antibody
US8680243B2 (en) 2007-11-14 2014-03-25 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-GPR49 antibody
CA2706549A1 (en) 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
CN104162155A (en) 2007-12-05 2014-11-26 中外制药株式会社 Therapeutic agent for pruritus
EP2236604B1 (en) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Liquid formulation containing a high concentration of antibody
RU2010133547A (en) 2008-01-11 2012-02-20 Дзе Юниверсити Оф Токио (Jp) Anti-cldn antibodies
MX2010007935A (en) * 2008-01-24 2010-08-23 Novo Nordisk As Humanized anti-human nkg2a monoclonal antibody.
US20100303828A1 (en) 2008-01-31 2010-12-02 INSERM Institut National de la Sante et de la Recherche Medicale) Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
PL2708558T3 (en) 2008-04-11 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2116261A1 (en) 2008-05-07 2009-11-11 Institut Pasteur Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
WO2009147781A1 (en) 2008-06-02 2009-12-10 国立大学法人東京大学 Antitumor agent
AU2009270181B2 (en) 2008-07-10 2014-05-29 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
PL2322221T3 (en) 2008-08-05 2015-01-30 Toray Industries Pharmaceutical composition for treatment and prevention of cancer
JP5730018B2 (en) 2008-09-30 2015-06-03 オリエンタル酵母工業株式会社 New chondrocyte proliferation and differentiation inducer
JP2012504946A (en) 2008-10-07 2012-03-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Neutralizing antibody against platelet factor 4 variant 1 (PF4V1) and fragments thereof
WO2010055950A1 (en) 2008-11-17 2010-05-20 財団法人ヒューマンサイエンス振興財団 Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
JP2010210772A (en) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
WO2010074049A1 (en) 2008-12-22 2010-07-01 株式会社 未来創薬研究所 Anti-hs6st2 antibody and use thereof
JP6009733B2 (en) 2008-12-25 2016-10-19 国立大学法人 東京大学 Diagnosis and treatment of cancer using anti-tm4sf20 antibody
WO2010074192A1 (en) 2008-12-26 2010-07-01 国立大学法人東京大学 Diagnosis and treatment of cancer using anti-lgr7 antibody
US8940501B2 (en) 2009-01-30 2015-01-27 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
EP3002296B1 (en) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla antibodies and uses thereof
WO2010113117A2 (en) 2009-03-30 2010-10-07 Edimer Biotech S.A. Preparation of isolated agonist anti-edar monoclonal antibodies
US9079957B2 (en) 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
RU2011151069A (en) 2009-05-15 2013-06-20 Чугаи Сейяку Кабусики Кайся Anti-axl antibody
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
US20120282173A1 (en) 2009-08-17 2012-11-08 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
WO2011057188A1 (en) 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies
WO2011080796A1 (en) 2009-12-28 2011-07-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
AR080428A1 (en) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulations Stabilized liquid contentivas antibody
AU2010344596B2 (en) 2010-01-29 2013-08-01 Toray Industries, Inc. Polylactic acid-based resin sheet
EP2530091B1 (en) 2010-01-29 2018-04-04 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
DK2532364T3 (en) 2010-02-04 2016-08-15 Toray Industries Pharmaceutical composition containing anti caprin-1 antibodies for treatment and / or prevention of cancer
US8828398B2 (en) 2010-02-04 2014-09-09 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR101801667B1 (en) 2010-02-04 2017-11-27 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of cancer
MX340017B (en) 2010-02-04 2016-06-22 Toray Industries Medicinal composition for treating and/or preventing cancer.
KR101842893B1 (en) 2010-02-04 2018-03-28 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of cancer
US8815211B2 (en) 2010-02-10 2014-08-26 Fujifilm Ri Pharma Co., Ltd. Radioactive metal-labeled anti-cadherin antibody
EP2540827A4 (en) 2010-02-26 2013-09-04 Chugai Pharmaceutical Co Ltd Anti-icam3 antibody and use thereof
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
EP2698431A4 (en) 2011-03-30 2014-10-01 Chugai Pharmaceutical Co Ltd Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
EP2796563A1 (en) 2010-05-04 2014-10-29 MedImmune, LLC Optimized degenerative muscle disease diagnostics and treatments
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
CN102959097B (en) 2010-07-08 2014-07-16 本田技研工业株式会社 High frequency heating coil
US9040671B2 (en) 2010-07-23 2015-05-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for cancer management targeting Co-029
US9675693B2 (en) 2010-09-30 2017-06-13 Riken Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
CA2816021A1 (en) 2010-10-25 2012-05-10 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
JP6006640B2 (en) 2010-10-29 2016-10-12 株式会社ペルセウスプロテオミクス Anti-CDH3 antibody with high internalization ability
TR201802772T4 (en) 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Blood coagulation factor VIII having an alternative function, for multi-specific antibody binding molecules in function.
WO2012073992A1 (en) 2010-11-30 2012-06-07 中外製薬株式会社 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CN109160951A (en) 2010-11-30 2019-01-08 中外制药株式会社 Cytotoxicity-inducintherapeutic therapeutic agent
MX358220B (en) 2011-11-30 2018-08-10 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex.
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
ES2684602T3 (en) 2010-12-22 2018-10-03 Orega Biotech Antibodies against human CD39 and use thereof
US9085772B2 (en) 2010-12-27 2015-07-21 National University Corporation Nagoya University Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell
JP6043629B2 (en) 2011-01-07 2016-12-14 中外製薬株式会社 Methods for improving antibody physical properties
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
EP2487242A1 (en) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
CN103974721A (en) 2011-09-30 2014-08-06 中外制药株式会社 Antigen-binding molecule for promoting loss of antigens
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
KR20140130707A (en) 2012-02-24 2014-11-11 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
TW201326209A (en) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
EP3590969A1 (en) 2011-03-31 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
WO2012133914A1 (en) 2011-03-31 2012-10-04 オリエンタル酵母工業株式会社 Potentiator of cancer immunity containing rankl antagonist
EP2694102A4 (en) 2011-04-04 2015-03-04 Univ Iowa Res Found Methods of improving vaccine immunogenicity
US10006879B2 (en) 2011-04-12 2018-06-26 Electronic Biosciences, Inc. Site specific chemically modified nanopore devices
US20140193420A1 (en) 2011-04-18 2014-07-10 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-itm2a antibody
CN103890010B (en) 2011-05-19 2017-04-19 法国国家健康医学研究院 Anti-human-HER3 antibodies and uses thereof
JP6334395B2 (en) 2011-06-17 2018-05-30 ノヴォ ノルディスク アー/エス Selective elimination of eroding cells
AU2012273954A1 (en) 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
JP6120833B2 (en) 2011-06-22 2017-04-26 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) Anti-Axl antibody and use thereof
KR102049122B1 (en) 2011-06-30 2019-11-26 추가이 세이야쿠 가부시키가이샤 Heterodimerized polypeptide
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Medicale) Antibodies for the treatment and prevention of thrombosis
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Medicale) Antibodies for the treatment and prevention of thrombosis
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Medicale) Antibodies for the treatment and prevention of thrombosis
JP6176849B2 (en) 2011-07-19 2017-08-09 中外製薬株式会社 A stable protein-containing preparation containing arginine amide or a similar compound
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
CA2844030C (en) 2011-08-04 2019-09-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
EP2740795B1 (en) 2011-08-04 2016-10-05 Toray Industries, Inc. Cancer treatment and/or prevention drug composition
WO2013017691A1 (en) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
MX348578B (en) 2011-08-04 2017-06-20 Toray Industries Pharmaceutical composition for treatment and/or prophylaxis of cancer.
WO2013024517A1 (en) 2011-08-12 2013-02-21 国立感染症研究所 Method for testing for, preventing, and treating infectious disease aspergillus fumigatus; and composition
US9550835B2 (en) 2011-08-23 2017-01-24 Chugai Seiyaku Kabushiki Kaisha Anti-DDR1 antibody having anti-tumor activity
EP2749641A4 (en) 2011-09-07 2015-07-01 Chugai Pharmaceutical Co Ltd Cancer stem cell isolation
WO2013047748A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CN104093424A (en) 2011-09-30 2014-10-08 中外制药株式会社 Antigen-binding molecule inducing immune response to target antigen
EP2762564A4 (en) 2011-09-30 2015-04-29 Chugai Pharmaceutical Co Ltd Ion concentration-dependent binding molecule library
EP3617313A1 (en) 2011-10-05 2020-03-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
WO2013062083A1 (en) 2011-10-28 2013-05-02 ファーマロジカルズ・リサーチ プライベート リミテッド Cancer stem cell-specific molecule
KR20140084249A (en) 2011-10-31 2014-07-04 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
TWI593705B (en) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US9512212B2 (en) 2012-01-11 2016-12-06 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
CN104204204A (en) 2012-02-09 2014-12-10 中外制药株式会社 Modified Fc region of antibody
HUE044611T2 (en) 2012-02-21 2019-11-28 Toray Industries Pharmaceutical composition for treatment of cancer
HUE034736T2 (en) 2012-02-21 2018-02-28 Toray Industries Medicinal composition for treating and/or preventing cancer
CA2865020A1 (en) 2012-02-21 2013-08-29 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2013223137B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
WO2013147153A1 (en) 2012-03-29 2013-10-03 株式会社未来創薬研究所 Anti-lamp5 antibody and utilization thereof
BR112014023937A2 (en) 2012-03-30 2018-04-17 Toray Industries pharmaceutical composition, pharmaceutical combination and treatment method
WO2013147176A1 (en) 2012-03-30 2013-10-03 東レ株式会社 Pharmaceutical composition for treatment and/or prevention of gall bladder cancer
CA2869704A1 (en) 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
CN104379741A (en) 2012-04-23 2015-02-25 基因先端领域株式会社 Anti-human cd69 antibody, and use thereof for medical purposes
CN104470950B (en) 2012-05-11 2017-04-26 公益财团法人微生物化学研究会 Anti-cxadr antibody
EP2857419A4 (en) 2012-05-30 2016-01-06 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for eliminating aggregated antigens
RU2014154067A (en) 2012-05-30 2016-07-20 Чугаи Сейяку Кабусики Кайся Target-specific antigen-binding molecule
EP2862875A4 (en) 2012-06-14 2016-01-13 Chugai Pharmaceutical Co Ltd ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
EP2861998A4 (en) 2012-06-18 2016-02-10 Electronic Biosciences Inc Cell-free assay device and methods of use
EP2864355B1 (en) 2012-06-25 2016-10-12 Orega Biotech Il-17 antagonist antibodies
US9840552B2 (en) 2012-07-30 2017-12-12 National University Corporation Nagoya University Monoclonal antibody against human midkine
WO2014030750A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
CA2882272A1 (en) 2012-08-24 2014-02-27 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
ES2684552T3 (en) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Antibodies directed against ICOS to treat graft versus host disease
WO2014042251A1 (en) 2012-09-13 2014-03-20 中外製薬株式会社 Gene knock-in non-human animal
JP6117222B2 (en) 2012-09-27 2017-04-19 中外製薬株式会社 FGFR3 fusion gene and drug targeting the same
EP2902787B1 (en) 2012-09-28 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Method for evaluating blood coagulation reaction
CN104937099B (en) 2012-11-09 2018-03-30 基因先端领域株式会社 Anti- ADAM28 antibody for treating cancer
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Medicale) Methods for the preparation of immunoconjugates and uses thereof
TWI664192B (en) 2012-11-20 2019-07-01 法商賽諾菲公司 Anti-ceacam5 antibodies and uses thereof
CN105849562B (en) 2013-12-24 2019-08-16 中外制药株式会社 The measuring method of soluble g PC3 protein
CA2896248A1 (en) 2012-12-27 2014-07-03 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
EP2940135A4 (en) 2012-12-27 2016-08-03 Chugai Pharmaceutical Co Ltd Heterodimerized polypeptide
US9932396B2 (en) 2013-02-08 2018-04-03 Medical & Biological Laboratories Co., Ltd. Antibody against human NRG1 protein
CN105073988A (en) 2013-02-15 2015-11-18 株式会社英仙蛋白质科学 Anti-CDH3 humanized antibody, drug conjugate thereof, and utilization of same
JP6490574B2 (en) 2013-02-28 2019-03-27 国立研究開発法人国立がん研究センター Antibodies against insoluble fibrin
WO2014163101A1 (en) 2013-04-02 2014-10-09 中外製薬株式会社 Fc region variant
WO2014174596A1 (en) 2013-04-23 2014-10-30 株式会社医学生物学研究所 Functional monoclonal antibody against heparin-binding epidermal growth factor-like growth factor
CN105264381B (en) 2013-05-16 2018-06-01 国立大学法人京都大学 For determining the method for cancer prognosis
US10005839B2 (en) 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
CA2916362A1 (en) 2013-06-24 2014-12-31 Masami Suzuki Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
CN105452294B (en) 2013-08-09 2019-08-02 东丽株式会社 The treatment of cancer and/or prophylactic compositions
WO2015041310A1 (en) 2013-09-20 2015-03-26 中外製薬株式会社 Treatment for hemorrhagic diseases by anti-protein-c antibody
JP6534615B2 (en) 2013-09-27 2019-06-26 中外製薬株式会社 Method for producing polypeptide heteromultimer
JPWO2015068781A1 (en) 2013-11-06 2017-03-09 国立大学法人大阪大学 Antibodies with broad neutralizing activity against group 1 of influenza virus type A
EP3066124A1 (en) 2013-11-07 2016-09-14 INSERM - Institut National de la Santé et de la Recherche Médicale Neuregulin allosteric anti-her3 antibody
CN105940107A (en) 2013-11-11 2016-09-14 中外制药株式会社 Antigen-binding molecule containing modified antibody variable region
TW201937018A (en) 2013-12-04 2019-09-16 日商中外製藥股份有限公司 Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
JP6514645B2 (en) 2013-12-27 2019-05-15 中外製薬株式会社 FGFR Gatekeeper Mutant Gene and Drug Targeting the Same
WO2015099165A1 (en) 2013-12-27 2015-07-02 中外製薬株式会社 Method for purifying antibody having low isoelectric point
EP3125936B1 (en) 2014-03-31 2019-05-08 Debiopharm International SA Fgfr fusions
US10544231B2 (en) 2014-04-16 2020-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
US10166304B2 (en) 2014-07-11 2019-01-01 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
TW201942137A (en) 2014-09-26 2019-11-01 日商中外製藥股份有限公司 Cytotoxicity-inducing therapeutic agent
CR20170326A (en) 2014-12-19 2017-08-22 Chugai Pharmaceutical Co Ltd myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
US10266584B2 (en) 2015-02-09 2019-04-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection
US20180071413A1 (en) 2015-04-07 2018-03-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Non-invasive imaging of tumor pd-l1 expression
WO2016166014A1 (en) 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
EP3319990A1 (en) 2015-07-07 2018-05-16 Institut National de la Sante et de la Recherche Medicale (INSERM) Antibodies having specificity to myosin 18a and uses thereof
US10509035B2 (en) 2015-08-07 2019-12-17 Gamamabs Pharma Sa Antibodies, antibody drug conjugates and methods of use
TW201823272A (en) 2015-09-18 2018-07-01 日商中外製藥股份有限公司 Il-8-binding antibodies and uses thereof
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
EP3378487A4 (en) 2015-11-18 2019-05-22 Chugai Seiyaku Kabushiki Kaisha Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
EP3395835A4 (en) 2015-12-25 2019-09-11 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
WO2017144668A1 (en) 2016-02-26 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for btla and uses thereof
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
MX2018011109A (en) 2016-03-28 2018-11-09 Toray Industries Pharmaceutical composition for treating and/or preventing cancer.
EP3491022A1 (en) 2016-07-29 2019-06-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Antibodies targeting tumor associated macrophages and uses thereof
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018079740A1 (en) 2016-10-28 2018-05-03 東レ株式会社 Pharmaceutical composition for cancer treatment and/or prevention
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
CA3039316A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN110392697A (en) 2017-03-02 2019-10-29 国家医疗保健研究所 There is the antibody and application thereof of specificity to NECTIN-4
US20200123248A1 (en) 2017-03-24 2020-04-23 Zenyaku Kogyo Co., Ltd. ANTI-IgM/B CELL SURFACE ANTIGEN BISPECIFIC ANTIBODY
CN110461358A (en) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 It can be used for preventing and/or treating the pharmaceutical composition of the polyspecific antigen binding molecules of the abnormal function comprising replacing platelet cofactor Ⅰ of factor IX
CN110944665A (en) 2017-04-14 2020-03-31 加马玛布斯制药公司 AMHRII-binding compounds for preventing or treating lung cancer
EP3609918A1 (en) 2017-04-14 2020-02-19 Gamamabs Pharma Amhrii-binding compounds for preventing or treating cancers
JPWO2018199214A1 (en) 2017-04-27 2020-03-12 中外製薬株式会社 Blood clotting factor IX with improved pharmacokinetics
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat hcmv related diseases
WO2019057933A1 (en) 2017-09-21 2019-03-28 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof
WO2019140150A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
IE913192A1 (en) * 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
CA2181787A1 (en) * 1994-03-03 1995-09-08 Claire M. Doerschuk Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5874080A (en) * 1994-03-03 1999-02-23 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of asthma

Also Published As

Publication number Publication date
US20020082396A1 (en) 2002-06-27
US5994524A (en) 1999-11-30
EP0770628B9 (en) 2007-02-28
EP0770628A1 (en) 1997-05-02
DE69535243T2 (en) 2007-05-10
CA2194907A1 (en) 1996-02-01
ZA9505832B (en) 1996-04-10
WO1996002576A1 (en) 1996-02-01
HUT77420A (en) 1998-04-28
EP0770628B1 (en) 2006-09-27
HU221385B1 (en) 2002-09-28
EP0770628A4 (en) 2004-10-27
US6245894B1 (en) 2001-06-12
AU2936395A (en) 1996-02-16
DE69535243D1 (en) 2006-11-09
AU701342B2 (en) 1999-01-28
KR100261941B1 (en) 2000-07-15

Similar Documents

Publication Publication Date Title
DK0590428T3 (en) Azaquinoxalins, methods for their preparation and their use
DE69217469D1 (en) Curved, absorbent body
DE69627248D1 (en) Absorbent, panty-like disposable undergarment
DE69531537D1 (en) Seat
DE69332861T2 (en) New urine protein, component b
DE69624640T2 (en) Improved damper
DE69508435D1 (en) Flexible, absorbent item
DK1131301T3 (en) 2-phenylbenzimidazoles and 2-phenylindoles, preparation thereof
DE69632932D1 (en) Noise damper
DE69526246D1 (en) Innovative photochrome, indeno-condensed naphthopyrane
DK0729951T3 (en) Naphthyl compounds, intermediates, preparations and methods
DE69729887D1 (en) Purin-l-nucleosides, their analogs and uses
FR2717075B1 (en) Aqueous organopolysiloxane makeup gel.
DK1027336T3 (en) Heter Garyldiazacycloalkanes, their preparation and use
DE69735996D1 (en) Human bikinine
DE122004000003I1 (en) Human antibodies which bind to human TNFalpha.
DE69636353D1 (en) Datenübetragungsvorrichtung.
DE69631896D1 (en) Murine model for human carcinomas
RU99107670A (en) High-productive protein expression
AT204723T (en) Prosthetic element for the treatment of honeybreaks, especially for coelioscopy
DE69721564D1 (en) Monovalent antibody fragments
FR2718635B1 (en) Cervical prosthesis.
DK0680969T3 (en) Modified oligonucleotides, their preparation and their use
DE69614590D1 (en) Walker
DK0802921T3 (en) human PAK65

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties